Tens of millions of people world-wide have been affected by the impact of thrombosis and hemorrhage. Vital clinical decisions can affect treatment outcomes and indeed life itself. Inspired by founder Dr. Thomas Exner’s passion to develop a screening test for early detection of thrombotic events, Haematex was established to provide niche products and services in the coagulation diagnostics industry.
The now widely used dRVT and newer DOAC-Stop™ first emerged from our Sydney based R&D efforts. These globally embraced products encourage us to keep innovating. We live for cultivating the culture of thinking “outside the box” where we grow new concepts which become the core of new product development.
To complement your testing needs, our existing product range includes bulk powder concentrates, liquid-stable reagents, sample pre-treatment agents, all of which are distributed globally. You may also find benefit from our custom-made reagents tailored to your specific requirements. Our quality IVD products supplied for the Australian market are registered on the Australian Register of Therapeutic Goods (ARTG). We also have a range of selected CE marked products for European distribution. Due to the nature of some of our products being based on Russell Viper venom, we comply with all CITES import and export regulations and all relevant permits are acquired accordingly. We are also compliant with all BICON regulations.
You will also find our range of high-quality products which we distribute for Hyphen Bio-Med and Bioporto Diagnostics an asset to your laboratory.
New website and logo launched
International Haematology Consultant appointed
DOAC-Stop™, SACT-II and HRRS being transitioned from CE to EUDAMED
Marie-Curie fellow Dr Manita Dangol appointed
International distribution network expanded into Africa
Contribution to COVID-19 effort - hand sanitiser distributed
Inhibitor Dots developed
DOAC-Stop™ manufactured as IVD and listed on ARTG
DOAC-Stop™ CE marked for European distribution
DOAC-Stop™ in development
HRRS - manufactured as IVD and listed on the ARTG
DOAC Test Developed.
Bioporto Diagnostics distribution agreement.
Ready for use dRVVT reagents developed.
Collagen Binding ELISA developed.
Hyphen-BioMed distribution agreement.
APTT first commercialised for South American market
Patented XACT test for procoagulant phospholipid.
Developed APTT reagents from dry powders
Haematex Research Pty Ltd established
Use this form to send us a message. All fields are required.